Skip to main content

Brain metastases

Current Treatment Options in Neurology volume 10, pages 308–314 (2008)Cite this article

Opinion statement

Metastatic brain tumors are the most common intracranial neoplasm in adults, affecting up to 10% of adults with cancer in the United States. The risk of developing brain metastases varies by primary cancer type, with lung cancer, breast cancer, and melanoma accounting for the majority. The incidence of brain metastases appears to be rising because of several factors, including an aging population, better treatment of systemic disease, and improved cranial imaging techniques. Therapeutic approaches to brain metastases include surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and chemotherapy. Many patients are treated with a combination of these, and treatment decisions must take into account clinical prognostic factors in order to maximize survival and neurologic function while avoiding unnecessary treatments. WBRT remains the most widely used treatment for patients with brain metastases. Although many radiation sensitizers have been studied over the years, none has emerged for widespread use. For patients with a limited number of brain metastases and favorable prognostic factors, local therapies such as surgery and SRS improve control rates and may extend survival compared with WBRT alone. SRS can also be used effectively at recurrence in patients with a limited number of lesions. Chemotherapy has traditionally played only a salvage role for brain metastases when all other treatments have failed, but research is likely to increasingly focus on systemic options such as targeted agents and angiogenesis inhibitors, as well as on novel delivery techniques and multidrug resistance pathways specific to brain in order to expand treatment options for this growing population of patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Gavrilovic IT, Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5–14.

    PubMed  Article  Google Scholar 

  2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al.: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865–2872.

    PubMed  Article  Google Scholar 

  3. Amer MH, Al-Sarraf M, Baker LH, et al.: Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660–668.

    PubMed  Article  CAS  Google Scholar 

  4. Chang EL, Wefel JS, Maor MH, et al.: A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007, 60:277–283, discussion 283–274.

    PubMed  Google Scholar 

  5. Mehta MP, Rodrigus P, Terhaard CH, et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529–2536.

    PubMed  Article  CAS  Google Scholar 

  6. Fife KM, Colman MH, Stevens GN, et al.: Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004, 22:1293–1300.

    PubMed  Article  CAS  Google Scholar 

  7. Lagerwaard FJ, Levendag PC, Nowak PJ, et al.: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43:795–803.

    PubMed  CAS  Google Scholar 

  8. Gaspar L, Scott C, Rotman M, et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751.

    PubMed  CAS  Google Scholar 

  9. Kaal EC, Niel CG, Vecht CJ: Therapeutic management of brain metastasis. Lancet Neurol 2005, 4:289–298.

    PubMed  Article  Google Scholar 

  10. Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494–500.

    PubMed  CAS  Google Scholar 

  11. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al.: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993, 33:583–590.

    PubMed  Article  CAS  Google Scholar 

  12. Barker FG 2nd: Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer 2004, 100:999–1007.

    PubMed  Article  Google Scholar 

  13. Borgelt B, Gelber R, Larson M, et al.: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981, 7:1633–1638.

    PubMed  CAS  Google Scholar 

  14. Patchell RA, Tibbs PA, Regine WF, et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485–1489.

    PubMed  Article  CAS  Google Scholar 

  15. Andrews DW, Scott CB, Sperduto PW, et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665–1672.

    PubMed  Article  Google Scholar 

  16. Rutigliano MJ, Lunsford LD, Kondziolka D, et al.: The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors. Neurosurgery 1995, 37:445–453, discussion 453–455.

    PubMed  CAS  Article  Google Scholar 

  17. Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886–1893.

    PubMed  CAS  Google Scholar 

  18. Rivera E, Meyers C, Groves M, et al.: Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006, 107:1348–1354.

    PubMed  Article  CAS  Google Scholar 

  19. Lassman AB, Abrey LE, Shah GD, et al.: Systemic highdose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006, 78:255–260.

    PubMed  Article  CAS  Google Scholar 

  20. Abrey LE, Olson JD, Raizer JJ, et al.: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001, 53:259–265.

    PubMed  Article  CAS  Google Scholar 

  21. Christodoulou C, Bafaloukos D, Kosmidis P, et al.: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001, 12:249–254.

    PubMed  Article  CAS  Google Scholar 

  22. Dziadziuszko R, Ardizzoni A, Postmus PE, et al.: Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003, 39:1271–1276.

    PubMed  Article  CAS  Google Scholar 

  23. Giorgio CG, Giuffrida D, Pappalardo A, et al.: Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005, 50:247–254.

    PubMed  Article  Google Scholar 

  24. Omuro AM, Raizer JJ, Demopoulos A, et al.: Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol 2006, 78:277–280.

    PubMed  Article  CAS  Google Scholar 

  25. Lin NU, Carey LA, Liu MC, et al.: Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract 503]. J Clin Oncol ASCO Annual Meeting Proceedings 2006, 24(June 20 Suppl).

  26. Shimato S, Mitsudomi T, Kosaka T, et al.: EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 2006, 8:137–144.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA

    Scott R. Plotkin

Authors
  1. April F. Eichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott R. Plotkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott R. Plotkin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eichler, A.F., Plotkin, S.R. Brain metastases. Curr Treat Options Neurol 10, 308–314 (2008). https://doi.org/10.1007/s11940-008-0033-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-008-0033-x

Keywords

  • Brain Metastasis
  • Temozolomide
  • Radiat Oncol Biol Phys
  • Levetiracetam
  • Main Drug Interaction